-
Metagenomi, Inc. (MGX) Tops Q2 EPS by 18c
-
CRISPR Therapeutics (CRSP) gains on continued chatter
-
Verve Therapeutics takeover has 'positive readthrough' for gene editing space - BMO Capital
-
Metagenomi, Inc. (MGX) Tops Q1 EPS by 7c
-
Metagenomi Inc (MGX) PT Lowered to $7 at H.C. Wainwright
-
Metagenomi (MGX) Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
-
Metagenomi (MGX) Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
-
Metagenomi, Inc. (MGX) Tops Q3 EPS by 24c
-
H.C. Wainwright Reiterates Buy Rating on Metagenomi Inc (MGX)
-
H.C. Wainwright Reiterates Buy Rating on Metagenomi Inc (MGX)
-
TD Cowen Reiterates Buy Rating on Metagenomi Inc (MGX)
-
Metagenomi (MGX) Reports Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months
-
Metagenomi Inc (MGX) PT Lowered to $7 at H.C. Wainwright
-
Metagenomi, Inc. (MGX) Tops Q2 EPS by 41c
-
H.C. Wainwright Reiterates Buy Rating on Metagenomi Inc (MGX)

